| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d1f301e2afba5e3bde4175a2de4b44dd |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-662
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-662
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2002-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22ec19ad68bfe1d3643bc553f1914fd2 |
| publicationDate |
2002-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-02062350-A1 |
| titleOfInvention |
Methods for the administration of amifostine and related compounds |
| abstract |
The present invention provides methods of administering aminoalkyl phosphorothioate and/or aminoalkyl thiol compounds to patients receiving radiation therapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1392324-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1392324-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7368440-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014204854-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7678779-B2 |
| priorityDate |
2001-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |